KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games (“Virtual Therapeutics”), today announced that it has successfully completed the tender offer commenced on June 3, 2024, to acquire all outstanding shares of common stock of Akili, Inc.

华盛顿州柯克兰（KIRKLAND）和波士顿（BUSINESS WIRE）--虚拟治疗公司（Virtual Therapeutics）是一家专注于通过引人入胜的沉浸式游戏（以下简称“虚拟治疗”）大规模改善心理健康的公司，今天宣布，它已成功完成2024年6月3日开始的收购要约，以收购Akili，Inc.的所有已发行普通股。

(Nasdaq: AKLI) (“Akili”) for $0.4340 per share (the “Offer Price”)..

（纳斯达克股票代码：AKLI）（“Akili”）每股0.4340美元（“发行价格”）。。

The tender offer expired at one minute after 11:59 p.m. EDT on July 1, 2024 (the “Expiration Date”). As of the Expiration Date, a total of 69,674,538 shares, representing approximately 88.2% of the outstanding shares of common stock of Akili, were validly tendered and not validly withdrawn. The number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied.

投标报价于2024年7月1日美国东部时间下午11:59（以下简称“到期日”）后一分钟到期。截至到期日，总计69674538股（约占Akili普通股流通股的88.2%）已被有效投标，未被有效撤回。。

Immediately after the Expiration Date, Virtual Therapeutics irrevocably accepted for payment all shares validly tendered and not validly withdrawn and expects to promptly pay for such shares..

到期后，Virtual Therapeutics立即不可撤销地接受所有有效投标且未有效撤回的股份的付款，并期望立即支付此类股份。。

Following completion of the tender offer, Alpha Merger Sub, Inc., a wholly owned subsidiary of Virtual Therapeutics (the “Purchaser”), will promptly merge with and into Akili (the “Merger”). The Merger is expected to occur on July 2, 2024. At the effective time of the Merger, each outstanding share of common stock of Akili that has not been validly tendered (other than shares owned by Akili, by Virtual Therapeutics, the Purchaser, any other subsidiary of Virtual Therapeutics or by any Akili stockholders who properly perfected their appraisal rights under the DGCL) will be converted automatically into the right to receive the Offer Price.

收购要约完成后，Virtual Therapeutics的全资子公司Alpha merge Sub，Inc.（以下简称“买方”）将立即与Akili合并（以下简称“合并”）。合并预计于2024年7月2日进行。在合并生效时，未经有效投标的Akili普通股流通股（除Akili、Virtual Therapeutics、买方、Virtual Therapeutics的任何其他子公司或适当完善其在DGCL下评估权的任何Akili股东拥有的股份外）将自动转换为接收要约价格的权利。

As a result of the Merger, Akili will become a wholly owned subsidiary of Virtual Therapeutics..

合并后，Akili将成为Virtual Therapeutics的全资子公司。。

Prior to the opening of trading on The Nasdaq Stock Market LLC (“Nasdaq”) on July 2, 2024, all shares of Akili common stock ceased trading on Nasdaq, and Virtual Therapeutics intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended..

在纳斯达克股票市场有限责任公司（“纳斯达克”）于2024年7月2日开始交易之前，Akili普通股的所有股票都停止了在纳斯达克的交易，Virtual Therapeutics打算立即将这些股票从纳斯达克摘牌，并根据经修订的《1934年证券交易法》注销。。

“The completion of this acquisition provides a foundation for us to build a leading digital health company that is capable of bringing new behavioral services to as many patients as possible,” said Dan Elenbaas, co-founder and CEO of Virtual Therapeutics. “We look forward to leveraging Akili’s expertise and strengths as we embark on this next stage of growth for Virtual Therapeutics.”.

Virtual Therapeutics联合创始人兼首席执行官丹·埃伦拜斯（DanElenbaas）表示：“此次收购的完成为我们建立一家领先的数字健康公司奠定了基础，该公司能够为尽可能多的患者提供新的行为服务。”。“我们期待着利用Akili的专业知识和优势，开始虚拟治疗的下一个增长阶段。”。

Advisors

顾问

TD Cowen is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel to Akili. Baker & McKenzie LLP is acting as legal counsel to Virtual Therapeutics.

TD Cowen担任独家财务顾问，Goodwin Procter LLP担任Akili的法律顾问。Baker&McKenzie LLP担任虚拟治疗的法律顾问。

About Akili

关于Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili’s approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment.

Akili通过改变游戏规则的技术开创了认知治疗的发展。Akili利用旨在直接针对大脑的技术的方法建立了一种新的医学类别-通过药物或医疗设备等临床试验验证但体验如娱乐的医学。

Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences..

Akili的平台由专有的治疗引擎提供动力，该引擎旨在针对大脑中认知障碍的来源，经过数十年的研究，并通过严格的临床程序进行验证。在Akili相信有效药物也可以有趣和吸引人的信念的推动下，Akili的产品通过迷人的动作视频游戏体验提供。。

About Virtual Therapeutics

关于虚拟疗法

Virtual Therapeutics is a digital health company delivering scalable, accessible, affordable, and personalized solutions for mental health and mental fitness. Leveraging extensive expertise as game developers, the company crafts and curates rich, appealing experiences that combine proven therapeutic techniques with modern gameplay mechanisms to delight and engage users.

Virtual Therapeutics是一家数字健康公司，为心理健康和心理健康提供可扩展、可访问、价格合理且个性化的解决方案。该公司利用游戏开发人员的丰富专业知识，精心打造和策划丰富而吸引人的体验，将成熟的治疗技术与现代游戏机制相结合，以取悦和吸引用户。

Virtual Therapeutics uses powerful cloud-based platform to gather and analyze various data streams to continuously measure, validate, and report effectiveness, seamlessly deploy and maintain its solutions, and provide users and partners with a truly turnkey experience. For more information, visit https://www.vthera.com/..

Virtual Therapeutics使用功能强大的基于云的平台来收集和分析各种数据流，以不断测量、验证和报告有效性，无缝部署和维护其解决方案，并为用户和合作伙伴提供真正的交钥匙体验。有关更多信息，请访问https://www.vthera.com/..

Forward-looking Statements

前瞻性声明

This communication contains “forward-looking statements” relating to the acquisition of Akili by Virtual Therapeutics. Such forward-looking statements include, but are not limited to, statements regarding the payment and timing of payment of the Offer Price to former Akili stockholders and the ability and timing of delisting of Akili’s common stock.

该通信包含与虚拟治疗公司收购Akili有关的“前瞻性声明”。此类前瞻性声明包括但不限于关于向前Akili股东支付要约价格和支付时间以及Akili普通股退市能力和时间的声明。

Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words..

实际事件或结果可能与这些前瞻性陈述存在重大差异。诸如“将”、“可能”、“会”、“应该”、“期望”、“计划”、“预期”、“打算”、“相信”、“估计”、“预测”、“项目”、“潜力”、“继续”、“未来”、“机会”等词语可能会产生”、“目标”，这些词语的变体，以及这些词语的类似表达或否定词，都是为了识别这些前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。。

Forward-looking statements are neither historical facts nor assurances of future performance and involve risks and uncertainties that could cause actual results to differ materially from those projected, expressed or implied by such forward-looking statements. Although Virtual Therapeutics and Akili believe that the expectations reflected in such forward-looking statements are reasonable, they cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions and the timing and results of any developments.

前瞻性陈述既不是历史事实，也不是对未来业绩的保证，涉及的风险和不确定性可能导致实际结果与此类前瞻性陈述所预测、明示或暗示的结果产生重大差异。虽然Virtual Therapeutics和Akili认为这些前瞻性陈述中反映的期望是合理的，但他们不能保证未来的事件、结果、行动、活动水平、绩效或成就、业务和市场状况以及任何发展的时间和结果。

Additional factors that may affect the future results of Akili are set forth in Akili’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including Akili’s most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov.

可能影响Akili未来业绩的其他因素载于Akili向美国证券交易委员会（“SEC”）提交的文件中，包括Akili最近提交的10-K表格年度报告、随后提交的10-Q表格季度报告、8-K表格当前报告以及向SEC提交的其他文件，这些文件可在SEC网站www.SEC.gov上查阅。

As a result of such risks and uncertainties, actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The forward-looking statements in this press release are subject to a number of risks and uncertainties, including, but not limited to, the risk that the timing of the payment or delisting may be delayed.

。本新闻稿中的前瞻性声明存在许多风险和不确定性，包括但不限于付款或退市时间可能延迟的风险。

Virtual Therapeutics and Akili caution investors not to unduly rely on any forward-looking statements..

Virtual Therapeutics和Akili提醒投资者不要过度依赖任何前瞻性陈述。。

The forward-looking statements contained in this release are made as of the date hereof, and Virtual Therapeutics and Akili undertake no obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise, except as expressly required by law. All forward-looking statements in this document are qualified in their entirety by this cautionary statement..

本新闻稿中包含的前瞻性声明自发布之日起发布，Virtual Therapeutics和Akili没有义务更新任何前瞻性声明，无论是由于未来事件、新信息还是其他原因，除非法律明确要求。本警示声明对本文件中的所有前瞻性陈述进行了整体限定。。